Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Inclusion Criteria: 18-65 years old, regardless of sex; Patients with lymphoma and multiple myeloma who need autologous hematopoietic stem cell transplantation; KPS score ≥70; creatinine clearance rate ≥ 50mL/min, total bilirubin level < 1.5mg/dL, ALT and AST < 2 times the upper limit of normal value; Absolute neutrophil count (ANC)≥1.5×109/L, platelet count ≥80×109/L, Hb≥ 75g/L, WBC ≥ 3.0× 109/L; Patients can tolerate chemotherapy; No active infection before chemotherapy; The patient voluntarily participated in this trial and signed the informed consent form; The researcher thinks that the subjects can benefit. Exclusion Criteria: Those who have previously received allogeneic or autologous hematopoietic stem cell transplantation; Serious or uncontrolled virus infection: HIV, syphilis positive; Severe dysfunction of internal organs; severe mental or nervous system diseases; allergic to PEG-rhG-CSF, rhG-CSF and other preparations or proteins expressed in Escherichia coli; pregnant or lactating female patients; Women of childbearing age refuse to accept contraceptive measures; Those who plan to become pregnant during the study period; The researcher judges other subjects who are not suitable to participate.